Los Angeles Capital Management
JANX icon

Los Angeles Capital Management’s Janux Therapeutics JANX Stock Holding History

Los Angeles Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$117K Sell
8,432
-1,524
-15% -$20.9K ﹤0.01% 1292
2025
Q4 		$284K Buy
+9,956
New +$234K ﹤0.01% 1120

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Los Angeles Capital Management's JANX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Janux Therapeutics (JANX) stake by 15% in Q1 2026, selling an estimated $20.9K and leaving 8,432 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1292.

Los Angeles Capital Management first reported a position in JANX in Q4 2025 and has held it in 2 quarters since. The position peaked at $284K in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Los Angeles Capital Management held 8,432 shares of Janux Therapeutics worth $117K as of Q1 2026.
  • Los Angeles Capital Management sold 1,524 Janux Therapeutics shares in Q1 2026, an estimated $20.9K.
  • Janux Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1292 holding.
  • Los Angeles Capital Management first reported a position in Janux Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Los Angeles Capital Management's Janux Therapeutics position peaked at $284K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.